Policymakers and Payers

This guideline updates the state of the science on pain research, care, and education with a particular focus on informing the Food and Drug Administration's (FDA's) development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.

The primary objectives of the SOURCE (Simulation of Opioid Use, Response, Consequences, and Effects) model are threefold: help the FDA and other stakeholders identify high-impact opioid-related interventions, assess potential unanticipated consequences of potential policies, and identify needs for further research.

This two-day public workshop convened regulators, academic researchers, clinicians, patient advocates, and other stakeholders to share information underlying this action and gather input related to the safe use of benzodiazepines.

The Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, is an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis.

This was a two-day virtual public workshop (which can now be re-watched) that focused on identifying gaps in existing opioid prescriber education offerings and core competencies that should be included in educational content for opioid prescribers and other healthcare providers, including prescriber education under a Risk Evaluation and Mitigation Strategy (REMS).

This was a two-day virtual public workshop (which can now be re-watched) that convened regulators, clinical researchers, providers, patient advocates, and other stakeholders to exchange information and obtain input by discussing prescriber education's potential role in alleviating the evolving opioid and substance use crisis.

This report describes changes in drug overdose death rates from 2019 to 2020, stratified by sex, age group, and race and ethnicity. In addition, it examines differences in circumstances surrounding drug overdose, and assesses differences in overdose death rates by county-level income inequality and availability of mental health treatment providers and providers of medications for opioid use disorder.

These estimated costs of opioid use disorder and fatal opioid overdose and their per capita costs at the state level can assist federal and state decision makers in understanding the magnitude of opioid use disorder and fatal opioid overdose in their jurisdictions.

This data visualization presents provisional counts for drug overdose deaths based on a current flow of mortality data in the National Vital Statistics System.

A fact sheet which outlines new strategies that can reduce the risks from polysubstance use.